Communiqués Autolus Therapeutics plc

Actions

AUTL

US05280R1005

Produits pharmaceutiques

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/07/2026			Varia. 5j.	Varia. 1 janv.
1,450 ^USD	-4,61%		+0,69%	-27,14%

24/07	Les actions européennes cotées aux États-Unis sous forme d'ADR progressent lors de la séance de vendredi	MT
21/07	Les actions européennes cotées aux États-Unis sous forme d'ADR progressent lors de la séance de mardi	MT

Communiqués

01/07	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
25/06	Autolus Therapeutics to Participate in Upcoming Investor Conference	GL
12/06	Autolus Therapeutics Receives Prix Galien UK Award	GL
27/05	Autolus Therapeutics to Participate in Upcoming Investor Conferences	GL
21/05	Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026	GL
14/05	Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates	GL
14/05	Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates	AQ
05/05	Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026	GL
29/04	Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction	GL
21/04	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
13/04	Autolus Therapeutics : Presentation - (260409 autl corporate presentation april 2026)	PU
07/04	Autolus Therapeutics to Participate in Upcoming Investor Conferences	GL
27/03	Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates	GL
16/03	Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026	GL
24/02	Autolus Therapeutics to Participate in Upcoming Investor Conferences	GL
04/02	Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
12/01	Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026	GL
06/01	Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform	BU
06/01	Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform	GL
08/12	Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025	GL
08/12	Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025	GL
01/12	Autolus Therapeutics Appoints Ryan Richardson to Board of Directors	GL
01/12	Autolus Therapeutics Appoints Ryan Richardson to Board of Directors	AQ
25/11	NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹	GL
25/11	NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹	AQ